0001104659-23-080096.txt : 20230711
0001104659-23-080096.hdr.sgml : 20230711
20230711200013
ACCESSION NUMBER: 0001104659-23-080096
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230707
FILED AS OF DATE: 20230711
DATE AS OF CHANGE: 20230711
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ozden Rabia Gurses
CENTRAL INDEX KEY: 0001814883
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36554
FILM NUMBER: 231083059
MAIL ADDRESS:
STREET 1: C/O AKOUOS, INC.
STREET 2: 645 SUMMER STREET SUITE 200
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OCULAR THERAPEUTIX, INC
CENTRAL INDEX KEY: 0001393434
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 24 CROSBY DRIVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
BUSINESS PHONE: 781-895-3235
MAIL ADDRESS:
STREET 1: 24 CROSBY DRIVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
FORMER COMPANY:
FORMER CONFORMED NAME: I-THERAPEUTIX INC
DATE OF NAME CHANGE: 20070315
4
1
tm2321019-1_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-07-07
0
0001393434
OCULAR THERAPEUTIX, INC
OCUL
0001814883
Ozden Rabia Gurses
C/O OCULAR THERAPEUTIX, INC.
24 CROSBY DRIVE
BEDFORD
MA
01730
0
1
0
0
Chief Medical Officer
0
Common Stock
2023-07-07
4
S
0
832
4.93
D
100531
D
Represents shares of common stock sold pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on July 1, 2023. The sales do not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.92 to $4.93, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
/s/ Donald Notman, Attorney-in-Fact for Rabia Gurses Ozden
2023-07-11